Abstract 1880P
Background
Physicians must help patients to maintain motivation and resolve barriers to adherence to treatment, but this does not happen in many cases. The impact of cancer in the coming years will have devastating consequences for the health system since it is the third cause of mortality in the country. Therefore, a substantial change in medical education, health policies is imperative. They are future specialists, the attitudinal barriers could limit their skills and abilities in the task for general surgeons, gynecologists, otolaryngologists, and anesthetists. To detect and change barriers, implement a strategy of 180 minutes in a reflexive focus group.
Methods
Descriptive, non-blind study approved by the Research Ethics Committee (ON23-00003), informed consent was requested from 51 medical residents of the surgical areas of a general hospital who attended a psychoeducational focus group in 2 frequencies, they answered the survey about their beliefs and attitudes regarding the care of cancer patients. 3 key questions were analyzed to ensure knowledge together with reflection, reinforcing empathic attitudes and team collaboration of the participants.
Results
The subjects correctly considered the definition of oncology pre and post-intervention (84 vs 91%), that the treating physician had to give the diagnosis (55 vs 92%) that there is no correct answer for how long a patient would live (89 vs 96%), The term used by the patient to name the cancer doesn´t matter as long as they understand the disease (32 vs 42%), That they should not join the conspiracy of silence proposed by the patient or family (77 vs 91%) If they believed that there is treatment in any stage of cancer (55 vs 87%), if they should care for patients with cancer with a CPR indication vs other chronic patients with hypertensive crisis and DM (64 vs 81%), if they considered palliative care and psycho-oncology for diagnostic phases (63 vs 85%). In the qualitative aspect they left satisfied and mostly looking forward to new sessions that would allow them to carry out their work and education.
Conclusions
There was a percentage impact in generating substantive changes in the opinion of the subjects; this first step should be followed up with more studies and is of relevance to medical educators.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Universidad Autónoma de Nuevo León.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2018P - Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Presenter: Jun Zhao
Session: Poster session 05
2019P - Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Presenter: Mónica Esteban García
Session: Poster session 05
2020P - Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2021P - Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2022P - ALBA project: Prognostic impact of laterality in small cell lung cancer
Presenter: Lorenza Landi
Session: Poster session 05
2024P - Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Presenter: Manuel Dómine
Session: Poster session 05
2025P - Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers
Presenter: Li Liu
Session: Poster session 05
2026P - Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Presenter: Lionel Falchero
Session: Poster session 05
2027P - Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis
Presenter: Patsy Lee
Session: Poster session 05